1.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
2.	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
3.	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
4.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
5.	Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RGI-2001-02, NCT01379209
6.	Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-001, NCT01416428
7.	Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 201303012, NCT01747499
8.	Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Phase: Phase II Type: Treatment Status: Active Age: 8 to 80 Sponsor: NHLBI Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
9.	Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and under Sponsor: NCI, Other Protocol IDs: 2212.00, NCI-2009-01244, P01CA018029, U19AI096111, NCT00968630
10.	Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma Phase: Phase II Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: MCC-16018, 108562, RV-MM-PI-0454, NCT01054144
11.	Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2010-0284, NCT01200485
12.	First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: VICC BMT 1020, NCT01215344
13.	Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 2206.00, NCI-2010-02222, P01CA018029, NCT01251575
14.	Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: UCBT01, NCT01328496
15.	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11D.247, 2011-31, NCT01384513
16.	Reduced Intensity Double Umbilical Cord Blood Transplantation Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 11-085, NCT01408563
17.	Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance After Autologous Stem Cell Transplantation Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-107, NCT01463670
18.	Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation Phase: Phase II Type: Treatment Status: Active Age: Under 75 Sponsor: Other Protocol IDs: 12-016, NCT01596257
19.	T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 2007LS022, MT2006-01, 0701M00303, UMN-2007LS022, UMN-MT2006-01, UMN-0701M00303, UMN-12559, UMN-6220-04, NCT00602693
20.	Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders Phase: Phase I Type: Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: 090210, 09-C-0210, NCT00973804
21.	Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation Phase: Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI Protocol IDs: 090224, 09-C-0224, NCT00984165
22.	Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies Phase: Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2009-0521, NCT01015222
23.	An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 101-99, NCT01090414
24.	Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies Phase: Phase I Type: Treatment Status: Active Age: any age Sponsor: Other Protocol IDs: 2009-0855, NCT01113476
25.	Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0108, NCT01183663